BUSINESSJul 21 · 11:00 UTCSCMP WORLDJulie Zhang

US biotech firm developing therapies for infant brain injuries plans Hong Kong listing

Axiom Biosciences, a US-based biotech firm developing AI-powered therapies for infant brain injuries, plans a primary Hong Kong IPO targeting $200 million in 2027, with a secondary US listing in 2029.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Axiom BiosciencesorganizationHong Kongplaceinfant brain injuriestopicArtificial IntelligencetopicUnited Statesplace

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJul 21 · 11:00 UTC
US biotech firm developing therapies for infant brain injuries plans Hong Kong listing
BUSINESSJul 21 · 10:45 UTC
US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom
HEALTHMay 14 · 11:00 UTC
STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
BUSINESSMay 4 · 10:45 UTC
Immune System Biotech Odyssey Seeks $238.3 Million in US IPO
BUSINESSJun 30 · 03:00 UTC
Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge